Van ECK Associates Corp Has $112,000 Stock Position in RxSight, Inc. (NASDAQ:RXST)

Van ECK Associates Corp raised its stake in RxSight, Inc. (NASDAQ:RXST) by 46.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,265 shares of the company’s stock after buying an additional 1,040 shares during the period. Van ECK Associates Corp’s holdings in RxSight were worth $112,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of RXST. Nisa Investment Advisors LLC lifted its holdings in shares of RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quarry LP lifted its holdings in shares of RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of RxSight during the third quarter worth $34,000. KBC Group NV lifted its holdings in shares of RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock worth $61,000 after purchasing an additional 479 shares during the period. Finally, Harbor Investment Advisory LLC acquired a new position in shares of RxSight during the fourth quarter worth $52,000. Institutional investors own 78.78% of the company’s stock.

Insider Activity

In other news, Director Shweta Maniar sold 3,782 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. This represents a 25.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jesse Anderson Corley acquired 1,443 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 13,506 shares of company stock worth $567,456. Company insiders own 9.36% of the company’s stock.

RxSight Trading Down 2.4 %

Shares of NASDAQ RXST opened at $29.60 on Monday. The firm’s 50-day moving average price is $33.14 and its 200-day moving average price is $43.76. RxSight, Inc. has a 1-year low of $26.29 and a 1-year high of $66.54. The firm has a market capitalization of $1.19 billion, a P/E ratio of -35.66 and a beta of 1.19.

Analyst Ratings Changes

A number of brokerages have recently commented on RXST. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Monday, January 13th. Stifel Nicolaus cut their price target on shares of RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, January 13th. UBS Group initiated coverage on shares of RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Wells Fargo & Company dropped their target price on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, RxSight currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.13.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.